Taiki Joho
Fukushima, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
First-in-human, open-label, single-arm phase 1 study of [211At] meta-astatobenzylguanidine in patients with pheochromocytoma or paraganglioma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 18, 2026
Straightforward PET phantom preparation using 68Gallium diluted with acid.
Journal: Annals of nuclear medicine
Published: February 28, 2026
Phase I/IIa clinical trial of 68Ga-PSMA-11 synthesized by a newly developed automated module using cyclotron-generated 68Ga.
Journal: Annals of nuclear medicine
Published: January 21, 2026
Production of 211At and automated radiosynthesis of [211At]MABG via electrophilic astatodesilylation.
Journal: EJNMMI radiopharmacy and chemistry
Published: June 15, 2025
Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma.
Journal: Annals of nuclear medicine
Published: February 18, 2025
Relationship between increased binding potential of possible 5-HT2A receptors in the ventral hippocampus by subchronic phencyclidine and disturbed social interaction in rats: a PET study using 18F-altanserin.
Journal: Cerebral cortex (New York, N.Y. : 1991)
Published: September 06, 2024
Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model.
Journal: European journal of nuclear medicine and molecular imaging
Published: July 23, 2024
Development of a Neopentyl 211At-Labeled Activated Ester Providing In Vivo Stable 211At-Labeled Antibodies for Targeted Alpha Therapy.
Journal: ChemMedChem
Published: May 14, 2024
Showing 1-8 of 8
Last Updated: 09/26/2026